NASDAQ:EQRX EQRx (EQRX) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free EQRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.34▼$2.3450-Day Range$2.04▼$2.4752-Week Range$1.58▼$5.55VolumeN/AAverage Volume3.30 million shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesOwnershipShort InterestSocial MediaStock AnalysisEarningsHeadlinesOwnershipShort InterestSocial Media Get EQRx alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About EQRx Stock (NASDAQ:EQRX)EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.Read More Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> EQRX Stock News HeadlinesFebruary 28, 2024 | finance.yahoo.comRevolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate ProgressMarch 29, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.February 26, 2024 | uk.finance.yahoo.comRevolution Medicines Inc (RVMD) Reports Earnings: R&D Investments Surge Amidst Clinical ProgressFebruary 21, 2024 | msn.comAbCellera Biologics (ABCL) Q4 2023 Earnings Call TranscriptFebruary 1, 2024 | morningstar.comGubra AS GUBRANovember 14, 2023 | msn.comSoftBank adds stakes in Neumora, Globalstar in Q3; stake in WeWork slashedNovember 9, 2023 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines and EQRx Stockholders Approve EQRx AcquisitionMarch 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… November 9, 2023 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines Completes Acquisition of EQRxNovember 8, 2023 | msn.comRevolution Medicines and EQRx stockholders approves acquisitionNovember 7, 2023 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate ProgressNovember 2, 2023 | finance.yahoo.comWe're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash WiselyOctober 20, 2023 | barrons.comCalling All EQRx, Inc. (EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesOctober 8, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, NEWR, EQRX, SCUSeptember 27, 2023 | benzinga.comEQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of ShareholdersSeptember 26, 2023 | finance.yahoo.comApplied BioMath, LLC Hosts 6th Annual Quantitative Systems Pharmacology SummitAugust 3, 2023 | businesswire.comEQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRXAugust 1, 2023 | msn.comRevolution Medicines will buy EQRx in an all-stock transactionAugust 1, 2023 | bizjournals.comEQRx sells to another Alexis Borisy biotech after multiple pivotsAugust 1, 2023 | finance.yahoo.comRevolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional CapitalAugust 1, 2023 | businesswire.comEQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to ShareholdersJune 29, 2023 | finance.yahoo.comEQRx, Inc. (NASDAQ:EQRX) has caught the attention of institutional investors who hold a sizeable 47% stakeMay 19, 2023 | seekingalpha.comCStone Breaks Up With Drugs Partner As U.S. Rollout StallsMay 10, 2023 | msn.comThe World Has Its Way With EQRxMay 9, 2023 | finance.yahoo.comQ1 2023 EQRx Inc Earnings CallMay 9, 2023 | markets.businessinsider.comEQRx Announces Massive Strategic Reset, Slashes Pipeline & WorkforceSee More Headlines Receive EQRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:EQRX CUSIPN/A CIK1843762 Webiii.cmlifesciencesspac.com Phone617-315-2255FaxN/AEmployees362Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-169,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.33% Return on Assets-19.32% Debt Debt-to-Equity RatioN/A Current Ratio18.77 Quick Ratio22.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book0.98Miscellaneous Outstanding Shares487,420,000Free Float398,218,000Market Cap$1.14 billion OptionableOptionable Beta0.48 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Alexis A. Borisy A.M. (Age 51)Founder & Executive Chairman of Board of Directors Ms. Melanie I. Nallicheri (Age 54)President, CEO, Principal Executive & Financial Officer and Director Comp: $931.75kMs. Dina Ciarimboli J.D. (Age 54)General Counsel & Corporate Secretary Comp: $628.63kMr. Robert Forrester LL.B. (Age 59)Co-Founder & Advisor Dr. Peter B. Bach M.D. (Age 58)MAPP, Co-Founder & Advisor Sir Andrew Dillon CBECo-Founder & AdvisorMr. Daniel Hoey (Age 56)Chief of Technical Operations Ms. Rona Anhalt (Age 58)Chief People Officer Dr. Carlos Garcia-Echeverria Ph.D. (Age 58)Chief of RX Creation Dr. Eric E. Hedrick M.D. (Age 58)Chief Physician Executive Comp: $575.1kMore ExecutivesKey CompetitorsSoleno TherapeuticsNASDAQ:SLNOIcosavaxNASDAQ:ICVXGracell BiotechnologiesNASDAQ:GRCLFate TherapeuticsNASDAQ:FATEVoyager TherapeuticsNASDAQ:VYGRView All Competitors EQRX Stock Analysis - Frequently Asked Questions What ETFs hold EQRx's stock? ETFs with the largest weight of EQRx (NASDAQ:EQRX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). This page (NASDAQ:EQRX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EQRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.